Coverage
-
September 20, 2023
The Federal Circuit on Wednesday relied on the high court's recent Amgen ruling to side with a Delaware federal court decision that let a Roche subsidiary off the hook in an infringement case over its blockbuster hemophilia drug Hemlibra.
1 other articles on this case.
View all »